StockWatch
·
Biotechnology: Pharmaceutical Preparations
ClarificationJul 30, 2026, 04:33 PM

Inventiva Corrects Debt Financing Tranche C to €55M; Reports H1 2026 Prelim Results

AI Summary

Inventiva S.A. filed an amendment to correct an error in a July 29, 2026 press release, stating the potential proceeds for Tranche C of its Debt Financing Transaction are €55 million, not €20 million. The company also reported preliminary financial results for the first half of 2026, with cash and cash equivalents totaling €166.1 million and €67.8 million in short-term deposits as of June 30, 2026. Inventiva expects to finance operations until Q2 2027 with current funds, extending to Q1 2028 if Tranche C and warrants are fully exercised, though current cash is not sufficient for the next 12 months.

Key Highlights

  • Corrected Tranche C debt financing potential proceeds to €55 million from €20 million.
  • Cash and cash equivalents: €166.1 million as of June 30, 2026.
  • Short-term deposits: €67.8 million as of June 30, 2026.
  • Net cash used in operating activities H1 2026: (€48.7) million.
  • Net cash generated from investing activities H1 2026: €63.9 million.
  • Net cash generated from financing activities H1 2026: €50.9 million.
  • Expected cash runway until Q2 2027 with current funds.
  • Expected cash runway until Q1 2028 with full Tranche C and warrants.
  • No revenues recorded for the first half of 2026.